Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment: Leukemia and Lymphoma

M Pennisi, L Berchicci, E Miserocchi, A Mussetti, V Cacioppo, A David, A Scialdone, I Lorusso, G Modorati, P Corradini, V Montefusco

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple myeloma (MM) therapy is evolving, and several new drugs are now available, extending patients’ life and exposure to different compounds and toxicities. We conducted a cross-sectional observational study enrolling 93 consecutive patients on active treatment for MM, aiming to assess their ocular complications. All the patients underwent a comprehensive ophthalmic evaluation. In our cohort, prevalence of low visual acuity was in line with similar age healthy population reported in registry studies. Interestingly, we recorded a higher prevalence of lens opacities (46%) and dry eye syndrome (53%). Nevertheless, we did not find any significant association between ocular disorders and anti-myeloma treatments, even steroid therapy. This observation suggests that other factors besides treatments, such as M-protein deposition in eye structures, may have a role in developing ocular toxicities. Since MM patients are elderly patients at higher risk of age-related eye disorders, we recommend periodic ophthalmic assessment in daily practice. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Original languageEnglish
Pages (from-to)477-482
Number of pages6
JournalLeuk. Lymphoma
Volume60
Issue number2
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment: Leukemia and Lymphoma'. Together they form a unique fingerprint.

Cite this